AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
(From Israel Business Arena)
Byline: Avishay Ovadia
Generic drug leader Teva (Nasdaq: TEVA; TASE:TEVA) received US Food and Drug Administration (FDA) approval to market generic Remeron on Friday. Sales of the ethical anti-depressant amount to $350 million a year.
Analysts estimate Teva's sales of generic Remeron will be $90-130 million a year, starting immediately.
Yesterday, Teva CFO Dan Suesskind said, "I believe we can achieve 80% market share within six months. The price [of generic Remeron] will be two-thirds of the ethical drug."
Teva will build its market share gradually, of course, which implies over $120 million in …